MDL | MFCD03848392 |
---|---|
Molecular Weight | 302.37 |
Molecular Formula | C17H22N2O3 |
SMILES | CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C |
HDAC 1.8 nM (IC 50 ) |
Trichostatin A is a potent and specific inhibitor of HDAC class I/II, with an IC 50 value of 1.8 nM for HDAC. Trichostatin A (TSA) inhibits proliferation of eight breast carcinoma cell lines with mean±SD IC 50 of 124.4±120.4 nM (range, 26.4-308.1 nM). HDAC inhibitory activity of Trichostatin A is similar in all cell lines with mean IC 50 of 2.4±0.5 nM (range, 1.5-2.9 nM) [1] . Trichostatin A (330 nM) increases Gαs protein expression in human myometrial cells, but does not increase Gαs mRNA levels [2] . Trichostatin A (20-75 nM) induces minimal cytotoxicity to adipose-derived stem cells (ADSCs), and enhances the osteogenic differentiation capacity of ADSCs [3] . In addition, Trichostatin A (0, 10, 100, 500 nM) dose-dependently decreases HDAC class I/II activity [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Trichostatin A (500 μg/kg, s.c.) pronounces antitumor activity without causing any measurable toxicity in doses of up to 5 mg/kg by s.c. injection, in randomized controlled efficacy studies using the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 25 mg/mL ( 82.68 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.3072 mL | 16.5360 mL | 33.0721 mL |
5 mM | 0.6614 mL | 3.3072 mL | 6.6144 mL |
10 mM | 0.3307 mL | 1.6536 mL | 3.3072 mL |